The liquid biopsy test is approved to identify patients who may benefit from treatment with specific FDA-approved targeted therapies.
The FDA recently approved the FoundationOne Liquid CDx, a comprehensive pan-tumor biopsy test, to identify patients who may benefit from treatment with specific FDA-approved targeted therapies, according to Foundation Medicine, the developer of the test.
The liquid biopsy test is now approved for rucaparib (Rubraca), a PARP inhibitor for the treatment of patients with BRCA 1/2-mutant metastatic castration-resistant prostate cancer, and 3 first-line tyrosine kinase inhibitors (TKIs) for the treatment of non-small cell lung cancer (NSCLC).
Notably, the FoundationOne Liquid CDx also acts as a comprehensive genomic profiling test that reports genomic alteration results, including genomic signatures such as blood tumor mutational burden and high microsatellite instability, as well as single gene alterations, including all NTRK fusions, for patients with any solid tumor to further aid in patient care.
In an interview with CancerNetwork®, Geoffrey R. Oxnard, MD, vice president and global medical lead for the liquid biopsy portfolio at Foundation Medicine, spoke about the liquid biopsy test and what it offers for both patients and providers.
This segment comes from the CancerNetwork® portion of the MJH Life Sciences Medical World News, airing daily on all MJH Life Sciences channels.
FDA Approves Foundation Medicine's FoundationOne®Liquid CDx, a Comprehensive Pan-Tumor Liquid Biopsy Test with Multiple Companion Diagnostic Indications for Patients with Advanced Cancer [news release]. Cambridge, Massachusetts. Published August 26, 2020. Accessed August 27, 2020. https://www.foundationmedicine.com/press-releases/445c1f9e-6cbb-488b-84ad-5f133612b721